Recent Posts

• Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress
• Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
• Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
• Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
• Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases